TY - JOUR T1 - Heterogeneity of Anticitrullinated Peptide Antibodies and Response to Anti-Tumor Necrosis Factor Agents in Rheumatoid Arthritis JF - The Journal of Rheumatology JO - J Rheumatol SP - 929 LP - 932 DO - 10.3899/jrheum.111315 VL - 39 IS - 5 AU - BENJAMIN A. FISHER AU - DARREN PLANT AU - KARIN LUNDBERG AU - PETER CHARLES AU - ANNE BARTON AU - PATRICK J. VENABLES AU - The Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS) Y1 - 2012/05/01 UR - http://www.jrheum.org/content/39/5/929.abstract N2 - Objective. To examine fine specificity of anticitrullinated peptide antibodies (ACPA) in relation to responsiveness to anti-tumor necrosis factor (anti-TNF) agents in rheumatoid arthritis (RA). Methods. Samples from 450 patients with RA treated with anti-TNF agents were analyzed for antibodies to citrullinated α-enolase, vimentin, and fibrinogen peptides. The Disease Activity Score-28 was measured at baseline and 6 months. Results. Both anti-cFib antibodies and the number of citrullinated peptides recognized were associated with a poorer response. These findings were not significant following stratification for anti-cyclic citrullinated peptide 2 antibodies. Conclusion. The presence of any ACPA rather than individual ACPA specificities was associated with a poorer response to anti-TNF agents. We suggest that this reflects distinctive differences in the pathogenesis of ACPA-positive and negative RA. ER -